Apomorphine Hydrochloride

Introduction Overview

Generic Name

apomorphine hydrochloride

Brand Name

Kynmobi

Dosage Form

sublingual film

Drug Class

Dopaminergic antiparkinsonism agents

Pharmacokinetics

Absorption:
Apomorphine hydrochloride administered via the sublingual film route demonstrates rapid absorption through the oral mucosa. The sublingual film formulation allows direct mucosal absorption, bypassing first-pass hepatic metabolism, resulting in a rapid onset of action ideal for acute management of "off" episodes in Parkinson's disease. Clinical pharmacokinetic studies indicate that apomorphine plasma concentrations peak generally within 30 minutes post-dose, aligning with the rapid alleviation of motor symptoms. The absorption is facilitated by the film's design that dissolves within approximately 3 minutes in the sublingual space. Factors such as saliva flow and mucosal integrity may impact the rate and extent of absorption.

Distribution:
Once absorbed, apomorphine exhibits a large volume of distribution, reflecting extensive tissue uptake including penetration into the central nervous system due to its lipophilic nature. Apomorphine crosses the blood-brain barrier efficiently, which is critical for its dopaminergic activity within the basal ganglia structures affected in Parkinson's disease. Protein binding in plasma is moderate and reversible. The distribution phase is rapid, facilitating prompt clinical effects. Distribution can be influenced by body composition and the presence of comorbid conditions affecting plasma protein levels.

Metabolism:
Apomorphine undergoes extensive hepatic metabolism primarily via conjugation pathways such as sulfation and glucuronidation. Cytochrome P450-mediated oxidative metabolism plays a minor role. Its metabolites are largely inactive. Metabolic clearance is high, contributing to a relatively short elimination half-life. Liver function impairment can affect apomorphine metabolism, necessitating careful monitoring and potential dose adjustments in patients with hepatic dysfunction. The presence of sodium metabisulfite as a stabilizing agent is noteworthy due to potential sulfite sensitivity.

Elimination:
The elimination of apomorphine and its metabolites occurs predominantly via renal excretion. The drug has a relatively short half-life, necessitating multiple doses in clinical use but spaced appropriately to avoid accumulation and adverse events. Renal impairment can reduce clearance, potentially increasing plasma concentrations and side effects. Therefore, kidney function assessment is recommended before and during treatment. The elimination profile supports the intermittent dosing used for acute "off" episodes, limiting continuous dopaminergic stimulation and associated side effects.

Dosage Forms

Available Dosage Forms:
Kynmobi is available exclusively as a sublingual film formulation, designed for rapid dissolution and absorption under the tongue. The films come in several dosages including 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg strengths, allowing titration according to patient response and tolerability. Each film is individually packaged in a foil pouch with child-resistant features to maintain stability and prevent contamination.

Dosages for Adults and Adolescents:
Kynmobi is indicated for adult patients with Parkinson's disease experiencing intermittent "off" episodes. The initial dose is determined by the healthcare provider, who will instruct the patient on proper administration technique and dosing frequency. Patients should not exceed more than one dose to treat a single "off" episode, must wait at least 2 hours before any subsequent dose, and should not exceed five doses per day. Dose titration may be guided by therapeutic response and side effect profile, with healthcare providers modifying doses between 10 mg to 30 mg as clinically indicated.

Specific Patient Populations:
Use in pediatric populations has not been established, and safety and efficacy in children are unknown. In patients with hepatic or renal impairment, careful monitoring is recommended though specific dosage adjustment guidelines are limited. Caution is advised in patients with cardiovascular issues, low blood pressure, or those prone to hypotension or syncope. The unique sublingual formulation accommodates patients with swallowing difficulties, a common concern in Parkinson's disease. Pregnant or breastfeeding women should use Kynmobi only if the potential benefit outweighs the risk due to insufficient safety data. Patients with sulfite allergies must avoid Kynmobi due to the presence of sodium metabisulfite as an inactive ingredient.

Mechanism Of Action

Apomorphine hydrochloride, the active component of Kynmobi, is a potent dopamine receptor agonist with preferential activity at D1 and D2 dopamine receptor subtypes in the central nervous system. Parkinson's disease is characterized by progressive dopaminergic neuron loss in the substantia nigra, leading to striatal dopamine deficiency and motor dysfunction. Apomorphine directly stimulates postsynaptic dopamine receptors, bypassing the disturbed endogenous dopamine synthesis pathway, thereby restoring dopaminergic signaling and improving motor symptoms.

At the molecular level, apomorphine binds to dopamine receptors located on neurons within the basal ganglia, enhancing neuronal excitability and modulating motor control pathways. It mimics dopamine's action by activating G-protein coupled receptors (GPCRs), triggering intracellular cascades that regulate neurotransmitter release, neuronal firing rates, and synaptic plasticity. This activation can help alleviate rigidity, bradykinesia, and tremor observed during "off" episodes.

The rapid onset of action of apomorphine administered via the sublingual route enables prompt symptom relief during acute motor fluctuations. Unlike levodopa, which requires conversion to dopamine and is subject to peripheral metabolism, apomorphine acts directly on receptors, leading to faster therapeutic effects. Additionally, compared to other dopaminergic agents, apomorphine's pharmacodynamics allow for flexible intermittent dosing to target episodic motor symptoms without the need for continuous dopaminergic stimulation.

Clinical studies demonstrate that apomorphine improves motor performance during "off" episodes and reduces the duration of these disabling periods. Its mechanism supports its integral role as a rescue therapy in Parkinson's disease. However, apomorphine's dopaminergic stimulation can also induce side effects such as nausea, hypotension, and neuropsychiatric manifestations, necessitating adjunctive antiemetic therapy and careful patient monitoring during dose titration.

Pharmacological Actions

Potent dopamine D1 and D2 receptor agonist activity, restoring dopaminergic neurotransmission.
Rapid onset of action via sublingual absorption bypassing first-pass metabolism.
Alleviates motor symptoms associated with Parkinson's disease 'off' episodes.
Modulates basal ganglia circuitry to improve motor function.
Induces intracellular G protein-coupled receptor signaling pathways.
Provides acute rescue therapy for intermittent motor fluctuations.
May influence non-motor symptoms via dopaminergic pathway modulation.
Promotes improved neuronal firing patterns in affected dopaminergic pathways.
Acts independently of presynaptic dopamine synthesis or release.
Reduces severity and duration of 'off' episodes in Parkinson's disease.
Can elicit side effects related to systemic dopaminergic stimulation.
Requires antiemetic co-administration to mitigate nausea induced by dopamine receptor activation.
Has potential effects on cardiovascular autonomic regulation via dopaminergic receptors.
Demonstrates efficacy in patients intolerant or insufficiently responsive to oral levodopa formulations.

Therapeutic Or Clinical Uses

Management of acute, intermittent 'off' episodes in Parkinson's disease patients.
Rescue treatment for sudden motor symptom deterioration during Parkinson's therapy.
Adjunctive therapy to oral levodopa/carbidopa regimens for motor fluctuations.
Alternative to subcutaneous apomorphine injections providing a less invasive delivery.
Treatment option for patients who have difficulty swallowing oral medications.
Used in adults with established Parkinson's disease requiring acute symptomatic relief.
Reduces duration and severity of motor 'off' states.
Can be incorporated into comprehensive Parkinson's management plans for motor symptom control.
Applicable in patients experiencing unpredictable and disabling 'off' episodes.
Suitable for flexible dosing tailored to patient-specific motor fluctuation patterns.
May improve quality of life by decreasing time spent in 'off' state daily.
Useful in combination therapy settings where motor symptoms are inadequately controlled.
Administered under healthcare provider supervision for dose titration and monitoring.
Prescribed in settings requiring rapid reversal of hypokinetic states.
Clinically indicated where prompt onset of dopaminergic stimulation is beneficial.

Side Or Adverse Effects

Nausea and vomiting, commonly requiring coadministration of antiemetic agents like trimethobenzamide.
Daytime sleepiness and sudden episodes of falling asleep without warning, potentially impairing safety.
Dizziness and orthostatic hypotension due to blood pressure-lowering effects.
Oral mucosal irritation including redness, swelling, soreness, dryness, ulceration, and pain.
Increased risk of falls, particularly in elderly parkinsonian patients with balance impairment.
Psychotic-like symptoms such as hallucinations, confusion, agitation, delusions, and disorganized thinking.
Impulse control disorders presenting as uncontrollable gambling urges, hypersexuality, or compulsive shopping.
Serious allergic reactions, especially in individuals with sulfite sensitivity, including anaphylaxis.
Potential for high fever, muscle rigidity, and confusion upon abrupt discontinuation or dose change (neuroleptic malignant syndrome-like symptoms).
Cardiovascular adverse events including rapid heartbeat, chest pain, and syncope.
Fibrotic complications affecting pleural, pericardial, and retroperitoneal tissues reported with prolonged dopamine agonist use.
Prolonged painful erections (priapism), requiring urgent medical attention.
Local adverse effects related to sublingual administration such as altered taste or salivation changes.
Possible exacerbation of existing psychotic or behavioral disorders.
Potential interactions leading to additive hypotensive effects with certain concomitant medications.

Precautions

Use cautiously in patients with history of severe allergic reactions or sulfite sensitivity due to sodium metabisulfite content.
Monitor for hypotension and dizziness, especially at treatment initiation and during dose escalations.
Assess risk factors for falls; implement fall prevention strategies in vulnerable patients.
Avoid concomitant use with 5HT3 antagonists such as ondansetron due to risk of severe hypotension and loss of consciousness.
Employ antiemetic therapy to reduce nausea and vomiting associated with dopaminergic stimulation.
Caution in patients with cardiac disease, arrhythmias, or history of syncope.
Use carefully in patients with psychotic disorders or history of hallucinations.
Gradual dose adjustments recommended to minimize neuropsychiatric and cardiovascular side effects.
Avoid alcohol consumption during therapy due to enhanced sedative and hypotensive effects.
Educate patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness.
Monitor hepatic and renal function as organ impairment may alter drug clearance.
Consider pregnancy and breastfeeding status due to lack of sufficient safety data.
Counsel patients on the potential for excessive daytime sleepiness; advise against driving or operating heavy machinery until effects are known.
Evaluate for impulse control disorders periodically during treatment.
Instruct on proper administration technique to avoid reduced efficacy and oral irritation.

Warnings

Do not use concomitantly with 5HT3 antagonists (ondansetron, granisetron, etc.) due to risk of severe hypotension and syncope.
Black box warning on sudden sleep episodes and somnolence that may impair ability to perform activities requiring alertness.
Risk of severe life-threatening allergic reactions, particularly in patients allergic to sulfites.
Potential to induce or exacerbate psychotic symptoms and behaviors.
Abrupt discontinuation or rapid dose reduction may precipitate neuroleptic malignant syndrome-like reactions.
Possible serious cardiovascular events including hypotension, tachycardia, and syncope.
Increased risk for fibrotic complications with chronic dopamine agonist exposure.
Prolonged and painful erections requiring urgent medical evaluation.
Must be kept out of reach of children due to potent dopaminergic effects and risk of overdose.
Patients must be instructed not to chew or swallow the film; improper administration can affect drug absorption and safety.
Excessive dosing beyond recommended limits may increase incidence of adverse effects and toxicity.
Use with caution in patients with hepatic or renal impairment; monitor closely.
Potential for drug interactions leading to enhanced adverse effects or reduced efficacy.
Warning against alcohol consumption which can potentiate sedative and hypotensive effects.
Patients with a history of asthma may have increased risk of sulfite-induced bronchospasm.

Contraindication

Known hypersensitivity to apomorphine hydrochloride or any component of the formulation.
Concomitant use of 5HT3 antagonist antiemetics such as ondansetron, granisetron, dolasetron, palonosetron, and alosetron.
Patients with history of severe allergic reactions to sulfites, given sodium metabisulfite in the formulation.
Severe hepatic or renal impairment where drug metabolism or elimination is significantly compromised.
Patients with known or suspected major psychotic disorders due to risk of symptom exacerbation.
Individuals with unstable cardiovascular conditions, including uncontrolled hypertension or cardiac arrhythmias.
Should not be used in pediatric patients due to lack of established safety and efficacy.
Patients experiencing acute confusional states or delirium.
Those who have demonstrated hypersensitivity reactions to other dopamine agonists.
Patients who are unable to follow sublingual administration instructions properly, risking dosing errors.

Drug Interactions

Severe hypotension and loss of consciousness when used with 5HT3 receptor antagonists such as ondansetron, granisetron, dolasetron, palonosetron, and alosetron.
Additive hypotensive effects when combined with nitrates like sublingual nitroglycerin, requiring monitoring and caution.
Potential pharmacodynamic interactions with other dopaminergic agents, increasing side effect risk such as hallucinations and dyskinesias.
Enhanced sedative effects when co-administered with CNS depressants including alcohol, benzodiazepines, and opioids.
May interact with antihypertensive medications, exacerbating blood pressure lowering and dizziness.
Concomitant use with antiemetics such as trimethobenzamide is often necessary to prevent apomorphine-induced nausea.
Possible interaction with drugs affecting cytochrome P450 enzymes; apomorphine metabolism is mainly by conjugation but enzyme inhibitors or inducers may affect clearance.
Use caution with other medications causing QT prolongation due to additive cardiac risks.
Drugs reducing gastric motility may affect sublingual absorption indirectly by altering mucosal conditions.
Dopamine antagonists such as antipsychotics can reduce therapeutic efficacy by receptor blockade.
Concurrent use with other medications causing orthostatic hypotension may potentiate risk.
Certain herbal supplements with CNS effects (e.g., St. John's Wort) may alter drug response.
Potential interaction with serotonergic agents requires monitoring due to theoretical risk of serotonin syndrome.
Drugs affecting renal function can alter apomorphine elimination and increase toxicity risk.
Monitoring is advised when combining with MAO inhibitors or COMT inhibitors used in Parkinson's treatment.

Preparations Of The Drug

Kynmobi sublingual film available in strengths of 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg apomorphine hydrochloride per film.
Packaged individually in child-resistant foil pouches to preserve stability and prevent contamination.
Each film is thin, flexible, and designed to dissolve completely under the tongue within approximately 3 minutes.
Inactive ingredients include disodium EDTA dihydrate, FD&C Blue #1, glycerol, glyceryl monostearate, hydroxyethyl cellulose, hypromellose, maltodextrin, (-) menthol, pyridoxine hydrochloride, sodium hydroxide, sodium metabisulfite, sucralose, and white ink.
Stable at room temperature between 68°F to 77°F (20°C to 25°C); films should remain inside foil pouch until use.
Dose strengths enable individualized titration based on patient tolerability and therapeutic response.
Foil pouches feature raised dots on wing tabs to facilitate opening while maintaining child resistance.
Instructions for use emphasize not cutting, chewing, or swallowing the film to ensure optimal absorption.
Includes clear patient information and stepwise administration guidelines to enhance compliance and safety.
Indicated for use in adults with Parkinson's disease experiencing intermittent motor 'off' episodes.
Storage recommendations include keeping films out of reach of children and pets to prevent accidental ingestion.
Additional supportive medications such as antiemetics (trimethobenzamide) are typically prescribed concurrently.
Formulation designed to improve patient adherence by providing a non-invasive alternative to injectable apomorphine.
Manufactured to pharmaceutical standards ensuring consistent apomorphine content and release characteristics.
Packaging includes child-resistant carton and internal trays with locking tabs to secure medication until dispensed.